A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients.

Trial Profile

A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs Methylnaltrexone bromide (Primary)
  • Indications Constipation
  • Focus Therapeutic Use
  • Sponsors Progenics Pharmaceuticals
  • Most Recent Events

    • 01 Aug 2018 Removed Valeant Pharmaceuticals International and Salix Pharmaceuticals from this study as, this study was completed in Feb 2005 and as per RDI, in Feb 2011, Salix Pharmaceuticals (Valeant Pharmaceuticals International ( subsidiary of Valeant Pharmaceuticals International ) received the worldwide rights of the drug from Progenics.
    • 09 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top